Based in France and the United Kingdom, Cellnovo is an innovative medical device company specialising in diabetes. Cellnovo has developed and markets the first connected all-in-one diabetes management system based on a patch pump that helps make life easier for patients. With its unique device Cellnovo allows optimal management of insulin injections whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real-time.
The system has CE mark, is reimbursed in most countries and is already being marketed in France and the United Kingdom. Operating on the most dynamical market segment, Cellnovo has a clearly-defined expansion strategy that involves accelerating the product’s commercialisation, initially in Europe and then in the United States and Asia, and increasing its production capacity to cope with the expected high level of demand.
In July 2015, Cellnovo joined the Euronext regulated market in Paris, in compartment C, raising €31.56 million through a capital increase.
Updated July 12, 2017
Stock Market: Euronext Paris, Compartment C
Number of shares: 16 545 356 (July 12, 2017)